A Rare Disease Day Webinar
Worldwide experts will come together for a free live webinar on February 28th to address rare disease clinical trials and the opportunity for innovative trial design and execution. Topics to be discussed include:
• Emerging opportunities for an “outside the box” approach to study and program design
• The importance of appreciating the illness, not just understanding the disease
• Family engagement informing both trial design as well as operational strategy
• Translating innovative designs into predictable high quality execution
Reserve your spot today!
Dr. Murphy’s professional career has spanned over 25 years in positions within the pharmaceutical industry. He is board-certified in psychiatry and has a doctorate in pharmacology, with training at Tulane University, Stanford University and the Mt. Sinai School of Medicine. His contributions as Chief Medical & Scientific Officer at Worldwide encompass all therapeutic areas under Worldwide’s umbrella, and include translational research activities, scientific regulatory support, and protocol development for phases I–IV. He has been a consultant for the Duke Clinical Research Institute and is Founder and Research & Development Editor for American Health and Drug Benefits™. As a lecturer within the Center for Experimental Pharmacology and Therapeutics, Harvard-MIT Division of Health Sciences and Technology (HST) for 17 years, Dr. Murphy contributed to the curriculum for a two-year Clinical Investigator Training Program.
Jeff Zucker has nearly 20 years of experience in clinical research operations focused on feasibility, patient recruitment, and site engagement. He began his career as a psychotherapist working with adolescents, children, and families. Mr. Zucker has held leadership positions with pharmaceutical companies, CROs, and research facilities, and has experience developing and conducting trials Phase I-IV. He has also provided significant consulting with physicians and investigative sites to start up and develop research operations.
Leslie has over 20 years in the pharmaceutical industry, working in biotech, pharmaceutical, and the CRO industry. She is responsible for the portfolio of rare disease and oncology studies within the immune mediated inflammatory disorder therapeutic area. She began her career in data management and moved into project management for a small CRO focused on biotech. She then moved to an oversight role at a large CRO where she worked as an oversight director for many large phase III programs, as well as development of oncology and rare disease molecules in all phases. She was the operational director for the rare disease-working group at a large CRO where she was responsible for global strategy, implementation, and risk mitigation for rare disease projects across therapeutic areas. Throughout her career, she has worked on over 30 studies and 5 NDA submissions and has operational experience in over 40 countries.
x
About Worldwide Clinical Trials
Worldwide Clinical Trials employs more than 1,400 professionals around the world, with offices in North and South America, Eastern and Western Europe, Russia and Asia. One of the world’s leading, full-service contract research organizations (CROs), we partner with sponsors in the pharmaceutical and biotechnology industries to deliver fully integrated clinical development and bioanalytical services, extending from first-in-human through phase IV studies. Grounded in medicine and science, we help sponsors move from medical discovery into clinical development and commercialization, helping bring innovative solutions to market that deliver enhanced value and improve patient lives. Our employees are among the best in their fields – clinicians, scientists, operational and regulatory specialists who offer expertise across a range of therapeutic areas, including neuroscience, cardiovascular diseases, immune-mediated inflammatory disorders (IMID), and rare diseases. For more information, visit our website at www.worldwide.com.